In vitro effect of a thrombin inhibition peptide selected by phage display technology

Thrombosis Research

Volumn 107, Issue 6, 2002, Pages 365-371

  Meiring, Muriel S ^a   Litthauer, Derek ^a   Hársfalvi, Jolan ^b   Van Wyk, Veronica ^a   Badenhorst, Philip N ^a   Kotzé, Harry F ^c  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c EMORY UNIVERSITY   (United States)

Author keywords

Bacteriophage M13 genetics; Peptide library; Phage display system; Recombinant fusion proteins; Thrombin; Thrombin antagonists and inhibitors

Indexed keywords

DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; THROMBIN INHIBITING PEPTIDE; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IN VITRO STUDY; PHAGE DISPLAY; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE RELEASE REACTION; VASCULAR ENDOTHELIUM;

BACTERIOPHAGES; BASE SEQUENCE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IMMUNOASSAY; PEPTIDE LIBRARY; PEPTIDES; PLATELET AGGREGATION; RECEPTORS, THROMBIN; THROMBIN TIME;

EID: 0037107254     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00349-3     Document Type: Article

References (23)

1. Doorbar J., Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J. Mol. Biol. 244:1994;361-369.
2. Goodson R.J., Doyle M.V., Kaufman S.E., Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. U. S. A. 91:1994;7129-7133.
3. Dennis M.S., Eigenbrot C., Skelton N.J., Ultsch M.H., Santell L., Dwyer M.A.et al. Peptide exosite inhibitors of factor VIIa as anticoagulants. Nature. 404(6777):2000;465-470.
4. Badimon L., Meyer B.J., Badiman J.J. Thrombin in arterial thrombosis. Haemostasis. 24:1994;69-80.
5. Bloom A.L. Physiology of blood coagulation. Haemostasis. 20(Suppl. 1):1990;14-29.
6. Davie E.W., Fujikawa K., Kissel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry. 30:1991;10363-10370.
7. Kotzé H.F., Lamprecht S., Badenhorst P.N., Roodt J.P., Van Wyk V. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons. Thromb. Haemost. 77:1997;1137-1142.
8. Kotzé H.F., Lamprecht S., Badenhorst P.N. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Blood. 85:1995;3158-3163.
9. Olsen S.T., Bjork I. Regulation of thrombin activity by antithrombin and heparin. Semin. Thromb. Hemost. 20:1994;373-408.
10. Weitz J.I., Hudoba M., Massel D., Maraganore J., Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by anti-thrombin III-independent inhibitors. J. Clin. Invest. 86:1990;385-391.
11. Markwardt F. Hirudin and derivates as anticoagulant agents. Thromb. Haemost. 66:1991;141-152.
12. Harsfalvi J., Stassen J.M., Hoylaerts M.F., Van Houtte E., Sawyer R.T., Vermylen J.et al. Calin from Hirudo medicinalis, an inhibitor of von Willebrand factor binding to collagen under static and flow conditions. Blood. 5:1995;595-603.
13. Maraganore J.M., Bourbon P., Jablonski J., Ramachandran K.L., Fenton J.W. II Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 29(30):1990;7095-7101.
14. Chirgadze N.Y., Sall D.J., Briggs S.L., Clawson D.K., Shang M., Smith G.F.et al. The crystal structures of human alpha-thrombin complexed with active site-directed diamino benzo[b]thiophene derivatives: a binding mode for a structurally novel class of inhibitors. Protein Sci. 9(1):2000, Jan. 29-36.
15. Dixon M, Webb EC. Enzymes. Longman Group: Academic Press; 1979. p. 334.
16. Fabioloa G.F., Bobde V., Damodharon L., Pattabhi V., Durani S. Conformational preferences of heterochiral peptides. Crystal structures of heterochiral peptides Boc-(D)-Val-(D)-Ala-Leu-Ala-Ome and Boc-Val-Ala-Leu-(D)-Ala-Ome enhanced stability of beta sheet through C-H-O hydrogen bonds. J. Biomol. Struct. Dyn. 18(4):2001, Feb. 579-594.
17. Das B., Merovitch H. Optimization of solvation models for predicting the structure of surface loops in proteins. Proteins. 43(3):2001, May 15;303-314.
18. Pearce J. Going round in circles to avoid proteolysis. Trends Biochem. Sci. 26(5):2001, May;282.
19. Priestle J.P., Rahuel J., Rink H., Tones M., Grutter M.G. Changes in interactions in complexes of hirudin derivatives and human alpha-thrombin due to different crystal forms. Protein Sci. 2(10):1993, Oct. 1630-1642.
20. Vagner J., Barany G., Lam K.S., Krchnák V., Sepetov N.F., Ostrem J.A.et al. Enzyme-mediated spatial segregation on individual polymeric support beads: application to generation and screening of encoded combinatorial libraries. Proc. Natl. Acad. Sci. U. S. A. 93:1996, August;8194-8199.
21. Cappiello M., Vilardo P.G., Lippi A., Criscuoli M., Del-Corso A., Mura U. Kinetics of human thrombin inhibition by two novel peptide inhibitors (hirunorm IV and hirunorm V). Biochem. Pharmacol. 52(8):1996, Oct. 25;1141-1146.
22. Nilsson T., Sjoling-Ericksson A., Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin. J. Enzyme Inhib. 13(1):1998, Feb. 11-29.
23. Francischetti I.M., Valenzuela J.G., Ribeiro J.M. Anophelin: kinetics and mechanism of thrombin inhibition. Biochemistry. 38(50):1999, Dec. 14;16678-16685.